Terms ending in 2027
Every in-force patent on Amgen Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,100,124 | Antibodies Directed to HER-3 and Uses Thereof In force · High confidence | Daiichi Sankyo Europe GmbH | In force | High confidence | |
| US 11,267,900 | Antibodies Directed to HER-3 and Uses Thereof In force · Medium confidence | Amgen Inc., | In force | Medium confidence | |
| US 9,988,462 | Material and Methods for Treating or Preventing HER-3 Associated Diseases In force · High confidence | Daiichi Sankyo Europe GmbH | In force | High confidence | |
| US 8,614,292 | An isolated protein comprising an activin type IIB5 receptor polypeptide and uses thereof In force · High confidence | Amgen, Inc. | In force | High confidence | |
| US 7,514,566 | Thiazole Compounds and Methods of Use In force · High confidence | Amgen Inc. | In force | High confidence | |
| US RE45,847 | Antibodies to Madcam In force · Low confidence | Amgen Fremont Inc. | In force | Low confidence | |
| US 8,946,151 | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen In force · Medium confidence | Northern Bristol N.H.S. Trust Frenchay Hospital | In force | Medium confidence | |
| US 7,928,205 | Methods for Refolding of Recombinant Antibodies In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,304,387 | Therapeutic Formulations of Keratinocyte Growth Factor In force · High confidence | Swedish Orphan Biovitrum AB (publ) | In force | High confidence | |
| US 10,072,090 | Human Anti-B7RP1 Neutralizing Antibodies In force · High confidence | Amgen Inc. | In force | High confidence | |
| 47 more term ends in 2027 · Pro | |||||
10 of 57 patents shown. Soonest term end first, then patent number.
Pro members see all 57, all of them expiring within the 18 months from Nov 21, 2026.
42 of these are in force and held by Amgen Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.